Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Groves

Showing results (551-560 of 569) with videos related to

Pageof 57
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|December 11, 2021
Correction to: FDG-PET/CT in colorectal cancer: potential for vascular-metabolic imaging to provide markers of prognosisShih-Hsin Chen, Kenneth Miles, Stuart A Taylor, et al.
The European Respiratory Journal|February 16, 2019
A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosisPauline T Lukey, Stephen A Harrison, Shuying Yang, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 14, 2017
Quantification of Lung PET Images: Challenges and OpportunitiesDelphine L Chen, Joseph Cheriyan, Edwin R Chilvers, et al.
The New England Journal of Medicine|February 1, 1996
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertensionR J Barst, L J Rubin, W A Long, et al.
Circulation|March 18, 1997
Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study GroupA L Hinderliter, P W Willis, R J Barst, et al.
Eclinicalmedicine|December 9, 2022
Multi-center evaluation of baseline neutrophil-to-lymphocyte (NLR) ratio as an independent predictor of mortality and clinical risk stratifier in idiopathic pulmonary fibrosisTheresia A Mikolasch, Peter M George, Jagdeep Sahota, et al.
Cell Systems|August 18, 2022
Archetype tasks link intratumoral heterogeneity to plasticity and cancer hallmarks in small cell lung cancerSarah M Groves, Geena V Ildefonso, Caitlin O McAtee, et al.
Annals of Internal Medicine|March 25, 2000
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trialD B Badesch, V F Tapson, M D McGoon, et al.
Journal of the American College of Cardiology|April 8, 2017
Detection of Atherosclerotic Inflammation by <sup>68</sup>Ga-DOTATATE PET Compared to [<sup>18</sup>F]FDG PET ImagingJason M Tarkin, Francis R Joshi, Nicholas R Evans, et al.
BMJ Open Respiratory Research|November 16, 2016
Accuracy and cost-effectiveness of dynamic contrast-enhanced CT in the characterisation of solitary pulmonary nodules-the SPUtNIk studyN R Qureshi, R C Rintoul, K A Miles, et al.
Pageof 57

Showing results (551-560 of 569) with videos related to

Sort By:
Pageof 57
European Journal of Nuclear Medicine and Molecular Imaging|December 11, 2021
Correction to: FDG-PET/CT in colorectal cancer: potential for vascular-metabolic imaging to provide markers of prognosisShih-Hsin Chen, Kenneth Miles, Stuart A Taylor, et al.
The European Respiratory Journal|February 16, 2019
A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosisPauline T Lukey, Stephen A Harrison, Shuying Yang, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 14, 2017
Quantification of Lung PET Images: Challenges and OpportunitiesDelphine L Chen, Joseph Cheriyan, Edwin R Chilvers, et al.
The New England Journal of Medicine|February 1, 1996
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertensionR J Barst, L J Rubin, W A Long, et al.
Circulation|March 18, 1997
Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study GroupA L Hinderliter, P W Willis, R J Barst, et al.
Eclinicalmedicine|December 9, 2022
Multi-center evaluation of baseline neutrophil-to-lymphocyte (NLR) ratio as an independent predictor of mortality and clinical risk stratifier in idiopathic pulmonary fibrosisTheresia A Mikolasch, Peter M George, Jagdeep Sahota, et al.
Cell Systems|August 18, 2022
Archetype tasks link intratumoral heterogeneity to plasticity and cancer hallmarks in small cell lung cancerSarah M Groves, Geena V Ildefonso, Caitlin O McAtee, et al.
Annals of Internal Medicine|March 25, 2000
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trialD B Badesch, V F Tapson, M D McGoon, et al.
Journal of the American College of Cardiology|April 8, 2017
Detection of Atherosclerotic Inflammation by <sup>68</sup>Ga-DOTATATE PET Compared to [<sup>18</sup>F]FDG PET ImagingJason M Tarkin, Francis R Joshi, Nicholas R Evans, et al.
BMJ Open Respiratory Research|November 16, 2016
Accuracy and cost-effectiveness of dynamic contrast-enhanced CT in the characterisation of solitary pulmonary nodules-the SPUtNIk studyN R Qureshi, R C Rintoul, K A Miles, et al.
Pageof 57